Related Experiment Video

Updated: Mar 14, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

19.0K

Remission in SLE: the duration depends on multiple factors, including the definition

Andrea Doria1, Margherita Zen1, Luca Iaccarino1

  • 1Rheumatology Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy.

Annals of the Rheumatic Diseases
|October 7, 2016
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Disease ActivitySystemic Lupus ErythematosusTreatment

More Related Videos

Murine Bilateral Renal Lymphadenectomy
06:20

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

130
Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

794

Related Experiment Videos

Last Updated: Mar 14, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

19.0K
Murine Bilateral Renal Lymphadenectomy
06:20

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

130
Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus
05:39

Dermoscopy Aids in the Diagnosis of Discoid Lupus Erythematosus

Published on: May 16, 2025

794

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

636
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
636
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

294
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
294

Articles linked to this work by shared authors, journal, and citation graph.

Do DMARDs increase the risk of cancer recurrence in patients with spondyloarthritis, psoriatic arthritis and rheumatoid arthritis?

Clinical and experimental rheumatology·2026

Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study.

Frontiers in immunology·2026

Switching from intravenous to subcutaneous infliximab in Behçet's disease: feasibility, safety and early outcomes.

Clinical and experimental rheumatology·2026

Advancing Care in Lupus Nephritis: Expert Perspectives on Current Practices and Future Directions in Italy.

Journal of clinical medicine·2026

Early belimumab accelerates renal response and reduces glucocorticoid exposure in lupus nephritis: a multicentre propensity-matched study.

Rheumatology (Oxford, England)·2026

Clinical and serological features of triple autoantibody-negative patients with systemic sclerosis: insights from the multicentric SPRING registry of the Italian Society for Rheumatology.

RMD open·2026

Low-dose blinatumomab in multidrug-resistant rheumatoid arthritis-a case series.

Annals of the rheumatic diseases·2026

Spatially distinct macrophage subsets drive myofibroblast heterogeneity and maladaptive fibrosis in lupus nephritis.

Annals of the rheumatic diseases·2026

Efficacy and safety of filgotinib in patients with active radiographic and nonradiographic axial spondyloarthritis: results from OLINGUITO, a phase 3 trial consisting of 2 randomised, placebo-controlled, double-blind, parallel-group studies.

Annals of the rheumatic diseases·2026

High-sensitivity flow cytometry in rheumatoid arthritis shows that early B-cell subset depletion is linked to 5-year rituximab response, while failure to deplete B cells occurs early in subsequent poly-refractory disease.

Annals of the rheumatic diseases·2026

Shared genetic architecture and therapeutic targets across paediatric immune-mediated diseases.

Annals of the rheumatic diseases·2026

Development and validation of minimal disease activity, disease flare, and minimal clinically important difference for children with chronic nonbacterial osteomyelitis using a consensus and data-driven approach.

Annals of the rheumatic diseases·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us